Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Replicative Cell Senescence

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The crucible of resilience: hormesis as the unifying principle of evolution, genetics, and epigenetics.

Archives of toxicology·2026

Same author

Hormesis in biomedical and toxicological models: A generalizable phenomenon induced by per- and polyfluoroalkyl agents.

Chemico-biological interactions·2026

Same author

Canine environmental health: An EPA blind spot? Canine physiology, environmental exposure, and the regulatory gap in U.S. policy.

Regulatory toxicology and pharmacology : RTP·2026

Same author

Hormetic effects of per- and polyfluoroalkyl substances on ecologically relevant animal models: Generality, quantitative features, and risk assessment implications.

Environmental pollution (Barking, Essex : 1987)·2026

Same author

How the US NAS BEAR I Genetics Panel scientific misconduct could have been avoided, but was not.

Journal of occupational and environmental hygiene·2026

Same author

BEAR I Genetics Panel: An unexpected and troubling historical twist: The untold story of Hermann Muller's significant scientific confusion.

Journal of occupational and environmental hygiene·2026

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Tumor resistance explained by hormesis.

Edward J Calabrese¹, Marc A Nascarella

¹Department of Public Health, Environmental Health Sciences, University of Massachusetts, Amherst, MA 01003, USA. edwardc@schoolph.umass.edu

Dose-Response : a Publication of International Hormesis Society

|March 12, 2010

Summary

This summary is machine-generated.

Drug resistance in medulloblastoma occurs via hormesis. This finding impacts chemotherapy design, relapse prediction, and patient outcomes.

Keywords:

GDC 0449 biphasic hedgehog pathway hormesis medulloblastoma tumor relapse

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Experiment Videos

Last Updated: Jun 15, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Area of Science:

Oncology
Pharmacology
Molecular Biology

Background:

Medulloblastoma is a common pediatric brain tumor.
Drug resistance is a major challenge in medulloblastoma treatment.
The chemotherapeutic agent GDC 0449 is used in medulloblastoma therapy.

Purpose of the Study:

To investigate the mechanism of enhanced drug resistance to GDC 0449 in a mouse model of human medulloblastoma.
To understand the implications of this resistance mechanism for treatment strategies.

Main Methods:

Utilized a mouse model for human medulloblastoma.
Administered the chemotherapeutic agent GDC 0449.
Analyzed the dose-response relationship and resistance mechanisms.

Main Results:

Enhanced drug resistance to GDC 0449 was observed.
The resistance mechanism was identified as a hormetic response.
Hormesis involves a biphasic response where low doses stimulate and high doses inhibit.

Conclusions:

Hormetic response underlies enhanced GDC 0449 resistance in medulloblastoma.
This finding necessitates adjustments in chemotherapy dosing and study design.
Understanding hormesis is crucial for improving medulloblastoma treatment outcomes and preventing relapse.